Background:

To date, Mexico has more than 1,280,000 confirmed cases and more than 116,000 deaths due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Limited information is available regarding Latin American patients with Guillain-Barré syndrome (GBS) and SARS-CoV-2.

Objective:

The objective is to describe the presentation, diagnosis, and outcome of patients with GBS associated with SARS-CoV-2 infection.

Methods:

We describe four cases of GBS associated with SARS-CoV-2 infection in Mexico.

Results:

Neurological symptoms initiated 2-17 days after the respiratory symptoms. The age group in or patients ranged from 26 to 41 years. Two patients presented with progressive, acute, and symmetric weakness and two with bilateral facial palsy. Patients with GBS diagnosis associated with SARS-CoV-2 infection have been reported to have a good outcome after IGIV or plasma exchange therapy.

Conclusion:

It is important to consider GBS as a potential manifestation of SARS-CoV-2 infection and recall that the diagnosis is based mainly on clinical evaluation. Laboratory and CSF analysis, as well as neurophysiologic studies, should be considered as a complement for diagnosis.

        · abstract in Spanish     · text in English     · English ( pdf )